% | $
Quotes you view appear here for quick access.

OncoGenex Pharmaceuticals, Inc. Message Board

  • lefty_rosenthal7 lefty_rosenthal7 Oct 30, 2013 2:12 PM Flag

    Oh this is Jolly Good News.. well Not Really

    TEVA's CEO abrubtly resigned today.
    This could be another key question to ask OGXI on 11/7/13
    Will this effect the partnership?
    Plus their stock (TEVA) hasn't been doing that great either.
    So what's the deal here?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • It wouldn't be so bad if it weren't related to the fact that it apparently grew out of a dispute between the CEO and the Board Chairman over the fastest way Teva can cut costs. Levin, the CEO who resigned (or more probably was fired at the Chairman's request according to Bloomberg), wasn't there yet when the Teva deal with OGXI was entered into in 2009. At that time, Teva said 011 would be the centerpiece of its new branded oncology program. There's not much left of that program because Levin deemphasized oncology and said Teva's focus would be elsewhere. So it's not as though OGXI has lost a great backer of 011. But Teva's profits have been plunging and the interim CEO was quoted by Bloomberg as saying Teva will pursue cost reductions "with a sense of urgency."

      All that said though, it's very doubtful this will have any effect on SYNERGY, which after all completed enrollment over a year ago and will report data in a few months. The AFFINITY trial is due to complete enrollment around the middle of next year so that's probably safe too. The ENSPIRIT lung cancer trial could be in jeopardy though you'd think Teva would want to see the results on SYNERGY before pulling the plug. Of course, if Teva were to cancel any of the trials it would be in breach of its contract with OGXI but it could probably negotiate a settlement that would cost it less than completing the trial. Teva did announce in its year-end presentation last year that it was terminating several partnership deals but it left the 011 trials in place

      The news could raise doubts about whether Teva would be willing or able to put much marketing muscle behind O11 if SYNERGY succeeds. But since Teva would collect most of the profits from 011 you'd think it would have every incentive to sell the product, especially since it's starved for new products that could help it turn around.

      It will be very interesting to hear what Cormack has to say about this.

    • I hope it affects any future partnering with TEVA. Glad for the funding, but TEVA is one of the reasons that 011 gets no respect (backing from a more respectable pharma would have lent more credibility to the ambiguous Ph II 011 data.) If OGXI doesn't go the rest of the way alone, I hope they at least steer clear of more tie-ups with TEVA.

      Sentiment: Hold

0.575-0.005(-0.88%)Aug 26 3:59 PMEDT